“compound 3d” is a prodrug which is phosphorylated in vivo to form a potent sphingosine-1-phopshate receptor modulator. BMS took two previous compounds into the clinic for MS with the goal of differentiating from fingolimod on safety. One potential issue for a previous compound was an overly long (12 day) half-life which could be undesirable [...]
Compound 3: A Sphingosine-1-Phosphate Receptor Modulator Prodrug
"compound 3d"
sphingosine-1-phosphate recep. mod. prodrug for multiple sclerosis, proj. human t1/2 of 5d from opt. of prior S1P1 modulators ACS Med. Chem. Lett., Aug. 11, 2020 Bristol-Myers Squibb, Princeton, NJ
Loading...
